A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE) (ILLUMINATE)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03913143 |
Recruitment Status :
Active, not recruiting
First Posted : April 12, 2019
Last Update Posted : January 11, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Leber Congenital Amaurosis 10 Blindness Leber Congenital Amaurosis Vision Disorders Sensation Disorders Neurologic Manifestations Eye Diseases Eye Diseases, Hereditary Eye Disorders Congenital Retinal Disease | Drug: sepofarsen Other: Sham | Phase 2 Phase 3 |
The purpose of this double-masked, randomized, controlled, multiple-dose study is to evaluate the efficacy, safety, tolerability and systemic exposure of sepofarsen (QR-110) administered via intravitreal injection in subjects with Leber's Congenital Amaurosis (LCA) due to the CEP290 p.Cys998X mutation after 24 months of treatment.
At study start subjects will be randomized to one of 3 treatment groups with either active study drug or sham treatment.
Sepofarsen (QR-110) will be administered via intravitreal (IVT) injection into the subject's treatment eye (the subject's worse eye).
Subjects in the sham-procedure group will undergo a procedure that will closely mimic the active injection.
After each dosing subjects will be assessed for safety and tolerability at follow up visits.
After the first eye has been treated for at least 12 months, treatment of the contralateral eye and cross-over of subjects assigned to sham may be initiated based on assessment of benefit/risk (including review of data from all clinical trials), and with concurrence of the Medical Monitor.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 36 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Double-masked, Randomized, Controlled, Multiple-dose Study to Evaluate Efficacy, Safety, Tolerability and Syst. Exposure of QR-110 in Leber's Congenital Amaurosis (LCA) Due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene |
Actual Study Start Date : | April 4, 2019 |
Estimated Primary Completion Date : | December 2021 |
Estimated Study Completion Date : | December 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: Group 1: Dose 1 sepofarsen (QR-110)
Initial loading dose, followed by maintenance doses at month 3 and every 6 months there after, administered by intravitreal injection (24 months duration of treatment). After 12 months treatment of the contralateral eye may be initiated
|
Drug: sepofarsen
RNA antisense oligonucleotide for intravitreal injection
Other Name: QR-110 |
Active Comparator: Group 2: Dose 2 sepofarsen (QR-110)
Initial loading dose, followed by maintenance doses at month 3 and every 6 months there after, administered by intravitreal injection (24 months duration of treatment). After 12 months treatment of the contralateral eye may be initiated
|
Drug: sepofarsen
RNA antisense oligonucleotide for intravitreal injection
Other Name: QR-110 |
Sham Comparator: Group 3: Sham
Sham Intravitreal Injection (no experimental drug administered), at month 0, month 3 and every six months there after. After 12 months cross over to active study drug may be initiated
|
Other: Sham
Sham intravitreal injection (no experimental drug administered) |
- Mean change in BCVA after 12 months [ Time Frame: 12 months ]Mean change in Best-corrected visual acuity (BCVA) relative to baseline after 12 months of treatment versus sham
- Percentage of subjects ≥-0.3 LogMAR change in BCVA vs sham [ Time Frame: 12 and 24 months ]Percentage of subjects with baseline BCVA ≥ 1.7 Logarithm of the minimum angle of resolution (LogMAR) with ≥ 0.3 LogMAR change in BCVA in treated versus sham
- Percentage of subjects <1.7 Logmar with clinical meaningful improvement in mobility course score [ Time Frame: 12 and 24 months ]Percentage of subjects with baseline BCVA < 1.7 LogMAR with a clinically meaningful improvement in mobility course score in treated versus sham
- Change in BCVA between two QR-110 dose groups [ Time Frame: 12 and 24 months ]Change in BCVA relative to baseline in the Dose 1 QR-110 dose group versus the dose 2 QR-110 dose group
- Change in BCVA to baseline in pooled QR-110 subjects [ Time Frame: 12 and 24 months ]Change in BCVA in both QR-110 dose groups pooled relative to baseline
- Change in mobility course score [ Time Frame: 12 and 24 months ]Change in mobility course score relative to baseline in the treatment eye versus sham
- Change in mobility course score binocular vision [ Time Frame: 12 and 24 months ]Change in mobility course score binocular vision versus baseline versus sham
- Rate of change in oculomotor instability from baseline [ Time Frame: 12 and 24 months ]Rate of change in oculomotor instability from baseline
- Full-field light sensitivity threshold (FST) testing for white light from baseline [ Time Frame: 12 and 24 months ]Full-field light sensitivity threshold (FST) testing for white light from baseline
- Full-field light sensitivity threshold (FST) testing for red light from baseline [ Time Frame: 12 and 24 months ]Full-field light sensitivity threshold (FST) testing for red light from baseline
- Full-field light sensitivity threshold (FST) testing for blue light from baseline [ Time Frame: 12 and 24 months ]Full-field light sensitivity threshold (FST) testing for blue light from baseline
- Change in photoreceptor inner/outer segment by OCT [ Time Frame: 12 and 24 months ]Change in photoreceptor inner segment/outer segment (inner segment [IS]/outer segment [OS]; ellipsoid zone [EZ] line) assessed by OCT relative to baseline
- Change in patient reported visual function via VFQ-25 (adults) [ Time Frame: 12 and 24 months ]Change in patient reported visual function, as measured by the Visual Function Questionnaire-25 (VFQ-25) score for adult subjects relative to baseline
- Change in patient reported visual function via CVAQC (pediatrics) [ Time Frame: 12 and 24 months ]Change in patient reported visual function, as measured by the Cardiff Visual Ability Questionnaire for Children (CVAQC) for pediatric subjects relative to baseline
- Change in the Patient Global Impressions of Severity (PGI-S) [ Time Frame: 12 and 24 months ]Change in the patient-reported outcome (PRO) Patient Global Impressions of Severity (PGI-S)
- Change in the Patient Global Impressions of Change (PGI-C) [ Time Frame: 12 and 24 months ]Change in the PRO Patient Global Impressions of Change (PGI-C)
- Change in ERG [ Time Frame: 12 months ]Change in Electroretinogram (ERG) via International Society for Clinical Electrophysiology of Vision [ISCEV] standard for full-field clinical ERG) relative to baseline
- Changes in ophthalmic examination findings [ Time Frame: 12 and 24 months ]Changes in ophthalmic examination findings
- Severity of ocular AEs [ Time Frame: 12 and 24 months ]Severity of ocular AEs
- Frequency of non-ocular AEs [ Time Frame: 12 and 24 months ]Frequency of non-ocular AEs

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 8 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Main Inclusion Criteria:
- Male or female, ≥ 8 years of age at Screening with a clinical diagnosis of LCA and a molecular diagnosis of homozygosity or compound heterozygosity for the CEP290 p.Cys998X mutation, based on genotyping analysis at Screening. Historic genotyping results from a certified laboratory are acceptable with Sponsor approval.
- BCVA greater or equal to Logarithm of the Minimum Angle of Resolution (LogMAR) +3.0, and equal or worse than LogMAR + 0.4 in the treatment eye.
- Detectable outer nuclear layer (ONL) in the area of the macula.
- An electroretinogram (ERG) result consistent with LCA. A historic ERG result may be acceptable for eligibility.
Main Exclusion Criteria:
- Any contraindication to IVT injection according to the Investigator's clinical judgment and international guidelines (Avery 2014).
- Any ocular and/or general disease or condition that could compromise subject's safety or interfere with assessment of efficacy and safety, as determined by the Investigator.
- Prior receipt of intraocular surgery or IVT injection within 3 months prior to study start or planned intraocular surgery or procedure during the course of the study.
- Use of any investigational drug or device within 90 days or 5 half-lives of Day 1, whichever is longer, or plans to participate in another study of a drug or device during the PQ-110-003 study period.
- Any prior receipt of genetic therapy for LCA.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03913143

Study Director: | ProQR Medical Monitor | ProQR Therapeutics |
Responsible Party: | ProQR Therapeutics |
ClinicalTrials.gov Identifier: | NCT03913143 |
Other Study ID Numbers: |
PQ-110-003 2018-003501-25 ( EudraCT Number ) |
First Posted: | April 12, 2019 Key Record Dates |
Last Update Posted: | January 11, 2021 |
Last Verified: | December 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
LCA10 CEP290 p.Cys998X c.2991+1655A>G Leber's Congenital Amaurosis |
Antisense oligonucleotide RNA therapy QR-110 sepofarsen |
Blindness Neurologic Manifestations Vision Disorders Sensation Disorders Eye Diseases Retinal Diseases Leber Congenital Amaurosis |
Eye Diseases, Hereditary Eye Abnormalities Genetic Diseases, Inborn Disease Pathologic Processes Nervous System Diseases Congenital Abnormalities |